Positive Study for Adolor and GSK Drug
Posted on: Thursday, 9 February 2006, 15:00 CST
A pivotal study of Entereg, GlaxoSmithKline and Adolor Corporation's treatment for the management of postoperative ileus, has produced positive top-line results. The results of the trial propelled shares in Adolor upwards by over 20%.
The companies were conducting the trial in an attempt to provide additional data to satisfy the FDA after the US regulators indicated in July last year that it would need more information on the drug before it could approve it.
In the study, which enrolled 654 patients scheduled to undergo large or small bowel resection surgery, the drug produced statistically significant acceleration in time to recovery of gastrointestinal function following bowel resection surgery.
"We believe these data address the FDA's request for additional data outlined in the approvable letter received by Adolor in July of 2005. We intend to submit the final results as part of our complete response to the FDA by June of 2006," stated Dr James Barrett, senior vice president, chief scientific officer and president, research of Adolor Corporation.
Entereg was generally well tolerated in this study. The most frequently reported adverse events both in the alvimopan and placebo groups were nausea, vomiting and abdominal distention.
Source: Datamonitor
Related Articles
- Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
- PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study of PEAK PlasmaBlade(TM) for Gynecologic Surgery
- Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
- Ikonisys Reports Positive Results From Clinical Study Designed to Evaluate the Efficacy of Circulating Tumor Cell Detection With Ikonisys' Automated Microscope
- Sanofi-Aventis Reports Positive Results From Depression Study
- Innovive Reports Positive Results From Cancer Study
- Spiration Inc. Announces Positive Results From Pilot Study of Treatment for Patients With Severe Emphysema at European Respiratory Society's Annual Congress
- NovaDel Announces Positive Results From Pharmacokinetic Study of Improved Sumatriptan Oral Spray Formulation
- Genomic Health, Inc. Announces Positive Results in Multiple Studies Presented at the American Society of Clinical Oncology Meeting
- GlaxoSmithKline and Adolor Report Initial Results From Phase 2 Studies of Entereg(TM) (Alvimopan)
 |
 |
User Comments (0)
RSS Feeds